Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

Metric
Company Name	Prometheus Biosciences, Inc.
Symbol	RXDX
MSH ID	COM:PROMETHEUSBIOSCIENCES
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	97
Website	prometheusbiosciences.com
LinkedIn
Founders

Metric
Market Cap	9.56B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	6.81M
Revenue (LTM)
Revenue (NTM)
Gross Profit	6.81M
EBITDA	-145.78M
Operating Income	-145.78M
Net Income	-141.75M
EPS	-3.49
Diluted EPS	-3.49
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1
Operating Profit Margin	-47.11
EBITDA Margin	-21.41
Net Profit Margin	-42.48
Return on Equity	-0.22
Return on Assets	-0.15
Return on Capital Employed	-0.17

COM:PROMETHEUSBIOSCIENCES

Prometheus Biosciences, Inc.

Last Close

199.74

15/06 20:00

Market Cap

9.56B

Beta: -

Volume Today

1.79M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-63.62
P/B Ratio	13.60
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.51K
EV Multiple	-75.84

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover	0.00

Metric
Operating Cash Flow	-123.25M
Free Cash Flow	-125.96M
Cash Flow to Debt	-3.55
Operating Cash Flow/Sales	-38.36
Free Cash Flow Yield	-0.01

Metric
Cash & Equivalents	292.42M
Accounts Receivable	50K
Inventory	-1.03M
Goodwill
Debt to Capitalization	0.04
Debt to Assets	0.04
Current Ratio	37.56
Quick Ratio	36.90

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	5.93
R&D to Revenue	30.37
SG&A to Revenue	11.28